Literature DB >> 7288622

The disposition of acyclovir in different species.

P de Miranda, H C Krasny, D A Page, G B Elion.   

Abstract

The absorption, distribution and biotransformation of the antiviral drug acyclovir were investigated in several species. Its oral administration resulted in better absorption and higher plasma levels in the dog and mouse than in the rat and rhesus monkey. Although more total drug was absorbed, the fraction of the oral dose of acyclovir absorbed declined with increasing doses of drug. When 14C-labeled acyclovir was given s.c. to mice and rats it was distributed into all the tissues examined, including the brain. In the dog, the drug was present in the cerebrospinal fluid, the aqueous humor and saliva after an oral dose. Binding of acyclovir to plasma proteins was less than 35%. In metabolism studies with radioactive acyclovir, high-performance liquid chromatography showed that 94 and 95% of the urinary radioactivity in mice and rats was unchanged acyclovir. Minor urinary metabolites were identified as 9-carboxymethoxymethylguanine and 8-hydroxy-9-(2-hydroxy-ethoxymethyl)guanine. There was no enhanced metabolism of the drug after its repeated daily administration to mice or dogs.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7288622

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  26 in total

1.  Computation of log BB values for compounds transported through carrier-mediated mechanisms using in vitro permeability data from brain microvessel endothelial cell (BMEC) monolayers.

Authors:  Helen H Usansky; Patrick J Sinko
Journal:  Pharm Res       Date:  2003-03       Impact factor: 4.200

2.  In Silico Absorption Analysis of Valacyclovir in Wildtype and Pept1 Knockout Mice Following Oral Dose Escalation.

Authors:  Bei Yang; David E Smith
Journal:  Pharm Res       Date:  2017-08-02       Impact factor: 4.200

3.  Nobel lecture in physiology or medicine--1988. The purine path to chemotherapy.

Authors:  G B Elion
Journal:  In Vitro Cell Dev Biol       Date:  1989-04

4.  Treatment of experimental cytomegalovirus infections with acyclovir.

Authors:  C A Bruggeman; W Engels; J Endert
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

5.  Selection of a derivative of the antiviral agent 9-[(1,3-dihydroxy-2-propoxy)-methyl]guanine (DHPG) with improved oral absorption.

Authors:  E J Benjamin; B A Firestone; R Bergstrom; M Fass; I Massey; I Tsina; Y Y Lin
Journal:  Pharm Res       Date:  1987-04       Impact factor: 4.200

6.  Prenatal toxicity of acyclovir in rats.

Authors:  R Stahlmann; S Klug; C Lewandowski; G Bochert; I Chahoud; U Rahm; H J Merker; D Neubert
Journal:  Arch Toxicol       Date:  1988       Impact factor: 5.153

7.  Nephrotoxicity of acyclovir and cis-diamminedichloroplatinum(II)--effect of co-administration in rats.

Authors:  J Hannemann; W Wunderle; K Baumann
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

8.  Efficacy of (-)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine in African green monkeys infected with simian varicella virus.

Authors:  K F Soike; R Bohm; J L Huang; B Oberg
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

9.  Mechanism of acyclovir uptake in rat jejunum.

Authors:  K C Meadows; J B Dressman
Journal:  Pharm Res       Date:  1990-03       Impact factor: 4.200

10.  Evaluation of SQ 34,514: pharmacokinetics and efficacy in experimental herpesvirus infections in mice.

Authors:  A Braitman; M R Swerdel; S J Olsen; A V Tuomari; J S Lynch; B Blue; T Michalik; A K Field; D P Bonner; J M Clark
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.